PHARMACOKINETICS
Absorption: after oral ingestion it is relatively rapidly absorbed as maximal plasma concentration (Cmax) is reached between 2.8 and 5.1 postdose
Bioavailability: 52%
Plasma protein binding: 96.3% -97%
Biological half-life: 1 hour
Metabolism: extensively metabolized by the liver. The drug metabolizing enzymes primarily responsible for Rabeprazole's metabolism are CYP2C19 and CYP3A4.


PHARMACODYNAMIC
Rabeprazole exerts its stomach acid-suppressing effects. It covalently binds to and blocks the (H+/K+) ATPase/ Proton pump at the secretory surface of gastric parietal cells. Hence it blocks the final step of gastric acid secretion.

Gastric ulcer (GU)
Peptic ulcer disease (PUD)
Maintenance of healing of erosive or ulcerative GERD
Healing of erosive and ulcerative GERD
Healing of duodenal ulcers
Treatment of symptomatic GERD
Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence

DOSAGE
PO 20 mg once daily in an empty stomach. The dosage and frequency changes as per the condition of patient

Bad, unusual or unpleasant(after) taste, drowsiness, bloating, constipation, fast heart beat, indigestion, nausea, seizures, skin rash, hives, sore throat & vomiting.

Clostridium difficile-associated diarrhoea.
In liver disease may require dosage reduction.
Cutaneous lupus erythematosus and systemic lupus erythematosus.
Hypomagnesemia
Increased risk of osteoporosis-related fracture of hip, wrist or spine.